Papers of note in Science Translational Medicine 9 (396)

Leslie K. Ferrarelli

doi:10.1126/scisignal.aao2249

This week’s articles describe ways to potentially treat lymphoma and fatty liver–associated fibrosis.

CANCER

Lymphoma’s loss is a therapeutic gain

Oricchio et al. discover that loss of SESTRIN1 expression drives mTORC1 signaling in lymphoma cells and that drugs inhibiting EZH2 may be therapeutic in patients by restoring the abundance of SESTRIN.

FIBROSIS

Opposing cytokines in obesity and fibrosis

Hart et al. report that inhibiting the growth factor TGF-β and the cytokine IL-13 may suppress the development of fibrosis in patients with nonalcoholic fatty liver disease.

Highlighted Articles

1. E. Oricchio,
2. N. Katanayeva,
3. M. C. Donaldson,
4. S. Sungalee,
5. P. P. Joyce,
6. W. Béguelin,
7. E. Battistello,
8. V. R. Sanghvi,
9. M. Jiang,
10. Y. Jiang,
11. M. Teater,
12. A. Parmigiani,
13. A. V. Budanov,
14. F. C. Chan,
15. S. P. Shah,
16. R. Kridel,
17. A. M. Melnick,
18. G. Ciriello,
19. H.-G. Wendel
, Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci. Transl. Med. 9, eaak9969 (2017).
OpenUrl FREE Full Text
1. K. M. Hart,
2. T. Fabre,
3. J. C. Sciurba,
4. R. L. Gieseck III,
5. L. A. Borthwick,
6. K. M. Vannella,
7. T. H. Acciani,
8. R. de Queiroz Prado,
9. R. W. Thompson,
10. S. White,
11. G. Soucy,
12. M. Bilodeau,
13. T. R. Ramalingam,
14. J. R. Arron,
15. N. H. Shoukry,
16. T. A. Wynn
, Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci. Transl. Med. 9, eaal3694 (2017).
OpenUrl Abstract/FREE Full Text

View Abstract

[1] E. Oricchio,
N. Katanayeva,
M. C. Donaldson,
S. Sungalee,
P. P. Joyce,
W. Béguelin,
E. Battistello,
V. R. Sanghvi,
M. Jiang,
Y. Jiang,
M. Teater,
A. Parmigiani,
A. V. Budanov,
F. C. Chan,
S. P. Shah,
R. Kridel,
A. M. Melnick,
G. Ciriello,
H.-G. Wendel
, Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci. Transl. Med. 9, eaak9969 (2017).
OpenUrl FREE Full Text

[2] E. Oricchio,

[3] N. Katanayeva,

[4] M. C. Donaldson,

[5] S. Sungalee,

[6] P. P. Joyce,

[7] W. Béguelin,

[8] E. Battistello,

[9] V. R. Sanghvi,

[10] M. Jiang,

[11] Y. Jiang,

[12] M. Teater,

[13] A. Parmigiani,

[14] A. V. Budanov,

[15] F. C. Chan,

[16] S. P. Shah,

[17] R. Kridel,

[18] A. M. Melnick,

[19] G. Ciriello,

[20] H.-G. Wendel

[21] K. M. Hart,
T. Fabre,
J. C. Sciurba,
R. L. Gieseck III,
L. A. Borthwick,
K. M. Vannella,
T. H. Acciani,
R. de Queiroz Prado,
R. W. Thompson,
S. White,
G. Soucy,
M. Bilodeau,
T. R. Ramalingam,
J. R. Arron,
N. H. Shoukry,
T. A. Wynn
, Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci. Transl. Med. 9, eaal3694 (2017).
OpenUrl Abstract/FREE Full Text

[22] K. M. Hart,

[23] T. Fabre,

[24] J. C. Sciurba,

[25] R. L. Gieseck III,

[26] L. A. Borthwick,

[27] K. M. Vannella,

[28] T. H. Acciani,

[29] R. de Queiroz Prado,

[30] R. W. Thompson,

[31] S. White,

[32] G. Soucy,

[33] M. Bilodeau,

[34] T. R. Ramalingam,

[35] J. R. Arron,

[36] N. H. Shoukry,

[37] T. A. Wynn

Papers of note in Science Translational Medicine 9 (396)

Highlighted Articles

Science Signaling

Article Tools